26 October 2021 - NICE has today published draft guidance for public consultation which does not recommend tucatinib (Tukysa; Seagen), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.

Tucatinib is licensed for treating HER2 positive locally advanced or metastatic breast cancer in people who have received at least 2 prior anti-HER2 treatments. The draft guidance concludes that people taking tucatinib combination have longer before their disease gets worse and live longer overall. However, how much longer people live is uncertain. 

Read NICE press release